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Abstract
Protein members of the AraC family of bacterial transcriptional activators have great promise as
targets for the development of novel antibacterial agents. Here, we describe an in vivo high
throughput screen to identify inhibitors of the AraC family activator protein RhaS. The screen
used two E. coli reporter fusions; one to identify potential RhaS inhibitors, and a second to
eliminate non-specific inhibitors from consideration. One compound with excellent selectivity,
OSSL_051168, was chosen for further study. OSSL_051168 inhibited in vivo transcription
activation by the RhaS DNA-binding domain to the same extent as the full-length protein,
indicating that this domain was the target of its inhibition. Growth curves showed that
OSSL_051168 did not impact bacterial cell growth at the concentrations used in this study. In
vitro DNA binding assays with purified protein suggest that OSSL_051168 inhibits DNA binding
by RhaS. In addition, we found that it inhibits DNA binding by a second AraC family protein,
RhaR, which shares 30% amino acid identity with RhaS. OSSL_051168 did not have a significant
impact on DNA binding by the non-AraC family proteins CRP and LacI, suggesting that the
inhibition is likely specific for RhaS, RhaR, and possibly additional AraC family activator
proteins.
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INTRODUCTION
The ever-growing problem of bacterial antibiotic resistance requires the identification and
development of novel antibacterial agents. Traditionally, the molecular targets for
antibacterial agents have been processes that are essential for bacterial growth. However,
inhibition of such essential processes exerts substantial selective pressure for the emergence
of resistance mechanisms that overcome the inhibition.1 One alternative strategy involves
targeting virulence factors. The non-essential nature of virulence factors may reduce
resistance development, but the substantial antigenic diversity they often exhibit can impede
their utility as anti-microbial targets.1 Alternatively, the activator proteins that are required
for the expression of bacterial virulence factors share the advantage of being non-essential,
but tend to be much more conserved than virulence factors.1 Unlike the dramatic and long-
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term effects traditional antibiotics can have, targeting the expression of virulence factors has
the potential to be considerably less disruptive to the gut microbiota. Thus, inhibitors of
activator proteins that are required by bacterial pathogens for the expression of virulence
factors have great potential to be developed into novel antibacterial agents.
Protein members of the large AraC family of transcriptional activators generally activate
expression of genes involved in carbon metabolism, stress responses, or virulence.2 Indeed,
large numbers of pathogenic bacteria, including many priority antibiotic resistant pathogens,
require AraC family transcription activators for virulence factor expression and thereby to
cause disease (for example,3,4). Many AraC family activators are required for the expression
of multiple virulence factors; thus, blocking the function of the AraC family activator has
the potential to substantially ameliorate virulence and disease. In support of this hypothesis,
deletion or inhibition of many AraC family activators of virulence factor expression has
been found to dramatically reduce infections (for example,5–11).
Several previously published studies have identified small molecule inhibitors of specific
AraC family virulence factor regulators12–17, and in several cases, demonstrated that they
can dramatically reduce infection in animal models. Among these, the
hydroxybenzimidazole class of inhibitors12–14,17 has been found to inhibit seven different
AraC family activators, suggesting that these inhibitors may target a relatively conserved
feature of the family. These studies, together with the above evidence that deletion of AraC
family activators can result in very large reductions in virulence, provide strong evidence
that AraC family activators can be effective targets for novel antibacterial agents. However,
it is likely that the currently available inhibitors will only be effective against a subset of the
medically important AraC family activators. This is based on the family’s extremely large
size and diversity – they are predicted to have arisen early in the evolution of bacteria2 and
paralogs typically share only 15–30% amino acid sequence identity. Thus, screening for
inhibitors of additional family members will likely identify new classes of inhibitors that
inhibit additional family members.
Our study involves the AraC family activators RhaS and RhaR, which activate expression of
the L-rhamnose catabolic operons in E. coli.18 RhaR activates expression of the operon that
encodes RhaS and RhaR, and RhaS activates expression of the operon that encodes the L-
rhamnose catabolic enzymes.18 Despite the fact that RhaS and RhaR appear to have arisen
by gene duplication, and both activate transcription in response to the effector L-rhamnose,
they share only 30% identity at the amino acid level.
Given that the ultimate success of developing previously identified AraC inhibitors into
antibacterial agents cannot be predicted, and the fact that inhibitors have only been
identified for a small fraction of the medically important family members, the goal of our
study was to identify novel small molecule inhibitors of AraC family activators. We used an
in vivo high-throughput screen to identify inhibitors of RhaS with the rationale that, similar
to the hydroxybenzimidazole class of inhibitors, some might inhibit multiple AraC family
activators. The in vivo screen circumvented the solubility problems that plague most AraC
family activators, and had the further advantage that only compounds that were able to
successfully enter Gram-negative bacterial cells would be identified. A secondary screen
differentiated the desired RhaS inhibitors from non-specific inhibitors. The most potent of
the inhibitors identified, OSSL_051168, was found to inhibit DNA binding by purified RhaS
and RhaR proteins, but not by the unrelated CRP or LacI proteins.
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Bacteria, growth media and growth conditions
All bacteria were strains of E. coli K-12, except strains for protein overexpression, which
were strains of E. coli B (Table S1). Cultures for the primary high-throughput screen were
grown in tryptone broth plus ampicillin (TB; 0.8% Difco tryptone, 0.5% NaCl, pH 7.0; all %
recipes are w/v except glycerol and DMSO, which are v/v). Cultures for subsequent in vivo
assays were grown in MOPS [3-(N-morpholino)propanesulfonic acid]-buffered minimal
medium as previously described.18 Cultures for phage P1vir infection were grown in
tryptone-yeast extract broth (TY; 0.8% Difco tryptone, 0.5% Difco yeast extract, 0.5%
NaCl, pH 7.0) supplemented with 5 mM CaCl2. Difco Nutrient Agar was used routinely to
grow cells on solid medium. Difco MacConkey Base Agar supplemented with 1% sorbitol
or maltose was used to screen for sorbitol- and maltose-deficient phenotypes. Ampicillin
(200 µg/mL), tetracycline (20 µg/mL), chloramphenicol (30 µg/mL), gentamycin (20 µg/
mL), L rhamnose (0.2%), glucose (0.2%), and isopropyl-β-D-thiogalactopyranoside (IPTG;
0.1 mM unless otherwise noted) were added as indicated. All cultures were grown at 37°C
with aeration, unless otherwise noted.
High-throughput screening compound library
High-throughput screening was performed using the compound library at the University of
Kansas High Throughput Screening Laboratory, which consisted of approximately 100,000
compounds. Compounds were purchased from ChemBridge Corp. (San Diego, CA),
Chemdiv, Inc. (San Diego, CA), Prestwick Chemicals (Illkirch, France) and MicroSource
Discovery Systems, Inc. (Gaylordsville, CT). Compounds were selected based on structural
diversity and drug-like properties.
Primary high-throughput screen
An overnight culture of E. coli strain SME3006 (Table S1) grown in TB with ampicillin was
diluted 1:100 into fresh TB with ampicillin that had been pre-warmed to 37°C. Cells were
grown to an OD600 of 0.1 and growth was stopped on ice for approximately 30 min. Using a
Multidrop 384 (Thermo Scientific, Hudson, NH), 35 µL of this cell culture was added to
each well of a 384-well plate (Nunc, Rochester, NY). In addition to cells, each well in
column 1 of the plate contained 20 µL 2.5% dimethyl sulfoxide (DMSO) and 10 µL water
(uninduced control); each well in column 2 contained 20 µL 2.5% DMSO and 10 µL 2% L
rhamnose (induced control); and each well in columns 3–24 contained 20 µL of a library
compound at 25 µg/mL in 2.5% DMSO and 10 µL 2% L rhamnose. Plates were incubated
statically for 3 h at room temperature to allow rhaB-lacZ induction, followed by addition of
25 µL lysis/ONPG (o-nitrophenyl-β-D-galactopyranoside) buffer [3 parts ZOB19 to 1 part
10 mg/mL lysozyme (Sigma, St. Louis, MO) dissolved in PopCulture cell lysis reagent
(EMD Chemicals, Inc., Gibbstown, NJ)]. After approximately 3 h of incubation at room
temperature, OD405 readings were taken for each well using an EnVision Multilabel Reader
(PerkinElmer, Waltham, MA). The average of the 16 induced and 16 uninduced wells on
each individual plate were used to calculate the percent activation for each well as follows:
Z-factors were calculated as in Zhang et al.20 for each individual 384-well plate screened.
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The tester strain for the primary high-throughput screen was SME3006. This strain carried
the RhaS-activated Φ(rhaB-lacZ)Δ84 fusion18 in single copy on the chromosome. The
rhaBAD promoter in this fusion includes the full binding site for the RhaS protein, but not
the upstream binding site for CRP. This ensures that RhaS is the sole activator of this fusion,
and that inhibition of CRP protein activity would not decrease LacZ expression. This strain
also carries ΔrhaS and recA::cat on the chromosome and RhaS expressed from plasmid
pHG165rhaS18, which modestly increases rhaB-lacZ expression levels compared with
chromosomal rhaS expression.
The control strain for the secondary high-throughput screen and subsequent experiments was
SME3359 (Table S1), and carries the LacI-repressed fusion and LacI-expressing
pHG165lacI. The fusion consists of lacZ under the control of an artificial promoter (Phts)
with an induced expression level similar to that of the induced rhaBAD operon. Phts is
regulated by LacI and induced with IPTG. The Phts core promoter elements include a near-
consensus -35 sequence (5’-TTGACT-3’) and a -10 sequence (5’-TACTAT-3’) followed by
a lacO1 operator sequence that overlaps the transcription start site with the same spacing as
lacO1 at lacZYA. To construct the upstream half of Phts, oligo 2829 (5’-
CGAgaattcATTTTAGGCACCCCAGGCTTGACT-3’) was annealed to oligo 2788 (5’-
CTAGAActcttcGTAGAGCCGGAAGCATAAAGAGTCAAGCCTGGGGTGCCTAAAAT
-3’) and the primers were extended using the Expand High Fidelity PCR System (Roche
Applied Science, Indianapolis, IN). (The complementary sequences in the oligos are
underlined; restriction endonuclease recognition sites are in lower case.) The downstream
half of the Phts promoter was constructed by similarly annealing and extending oligos 2789
(5’-
CTAGAActcttcACTACTATGTGTGGAATTGTGAGCGATAACAATTTCACACAGGAA
ACAGC-3’) and 2790 (5’-
CTAggatccTTCATAGCTGTTTCCTGTGTGAAATTGTTATCG-3’). The PCR products
were cleaned up with a QIAquick PCR Purification Kit (Qiagen, Inc., Valencia, CA),
digested with EarI, EcoRI, and BamHI (New England Biolabs, Ipswich, MA), and then
ligated to EcoRI- and BamHI-digested pRS414 (Table S1). The sequence of both DNA
strands of the cloned region was confirmed (Northwestern University Genomics Core,
Chicago, IL). Phts-lacZ was recombined onto λRS45 and integrated as a single-copy
lysogen21 into the chromosome of strain SME1085. Likely single-copy lysogens were
identified by β galactosidase assay18 and confirmed by PCR22. The resulting strain was
transformed with LacI-expressing pHG165lacI.
Secondary high-throughput screen
We re-screened the top ~5% most inhibitory compounds from the primary screen. The
secondary screen was performed essentially as the primary screen, except for the following
changes: Cells were grown in MOPS-buffered minimal medium with ampicillin rather than
TB with ampicillin. Compounds were tested against both SME3006 and SME3359. For
plates containing SME3359, 6.5 mM IPTG was used as the inducer rather than 2% L
rhamnose, and the first and second columns were uninduced and induced controls,
analogous to above.
Strain construction for in vivo dose-response studies
For dose-response studies, a rhaB-lacZ reporter strain was designed that allowed IPTG
induction of RhaS or RhaS(163–278) expression from pHG165 (and thus rhaB-lacZ
expression). The strain was constructed by introducing malP::lacIq from strain SG22166 into
SME3000 via phage P1vir-mediated generalized transduction, by the previous method.23
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The resulting strain, SME3000 malP::lacIq zhc-511::Tn10, was transduced with recA::cat
from SME1048 by selecting for chloramphenicol resistance, to make strain SME3632.
In vivo Dose-response experiments
The top hit identified in the screen was 1-ethyl-4-nitromethyl-3-quinolin-2-yl-4H-quinoline.
The closely related compound, OSSL_051168, 1-butyl-4-nitromethyl-3-quinolin-2-yl-4H-
quinoline, was obtained from eMolecules, Inc. (Solana Beach, CA; catalog #3761-0013) or
Princeton BioMolecular Research (Princeton, NJ; catalog #OSSL_051168), with the
Princeton named used here. OSSL_051168 was dissolved in 100% DMSO and then the
solution was further diluted in 100% DMSO in a 2-fold series for a total of seven
concentrations. Dose-response assays were performed in 96-well plates with one column
each of uninduced and induced controls for each strain, and one column with a concentration
curve of OSSL_051168 for each strain. Uninduced wells contained 20 µL water and 40 µL
10% DMSO; induced wells contained 20 µL induction solution (2% L rhamnose and 6.5
mM IPTG) and 40 µL 10% DMSO; concentration curve wells contained 20 µL induction
solution, 36 µL water and 4 µL diluted OSSL_051168. The appropriate cell culture (70 µL,
grown to OD600 = 0.1 in MOPS-buffered minimal medium with ampicillin) was added to
each well and induced for 3 h at 37°C. Lysis/ONPG buffer (50 µL, as in Primary Screen)
was added to each well and the plate was immediately placed into a PowerWave XS plate
reader (BioTek Instruments, Inc., Winooski, VT), set to read the OD420 of each well every
15 min for 4 h. A single time point within the linear range of β-galactosidase activity was
chosen for analysis for each strain. Due to differences in kinetics of lacZ reporter
expression, the rhaB-lacZ strains were analyzed at 4 hours and the hts-lacZ strain was
analyzed at 1 h. Percent activity was calculated for each condition as described above, using
the single time point with appropriate OD420 levels for each strain. Error bars represent the
standard error of the mean. IC50 and maximal inhibition values were calculated using the
XLfit add-in for Microsoft Excel (ID Business Solutions, Guildford, UK), and graphs were
drawn using Prism (GraphPad, La Jolla, CA).
Growth Curves
Strains SME3634 and SME3359 were grown overnight (~16 h) at 37 °C in MOPS-buffered
minimal medium.18 Overnight grown cultures were diluted into the same medium plus
rhamnose to an O.D600 of 0.1, and IPTG was added. 1 mL aliquots of the cultures were
added to wells of a 24-well plate, with the addition of either 44 µM OSSL_051168
(dissolved in 100% DMSO) or an equal volume of 100% DMSO. Growth was monitored at
20 min intervals for approximately 8 h at 37 °C with continuous shaking in a PowerWave
XS plate reader (BioTek Instruments, Inc., Winooski, VT). Error bars represent the standard
error of the mean.
Protein purification
All proteins for this study were expressed in E. coli. Untagged CRP was purified by Ni2+-
affinity chromatography as described.24 LacI protein was purified by ammonium sulfate
precipitation and phosphocellulose column chromatography as described.25 RhaS-GB1201b
and GB1b-RhaR were purified by Ni2+-affinity chromatography. Briefly, plasmids derived
from pET21 and expressing RhaS-GB1201b and GB1b-RhaR were transformed into
competent cells of strains Acella™ (MoBiTec, Göttingen, Germany) or ArcticExpress(DE3)
(Agilent Technologies, Santa Clara CA), respectively. The cells were grown in 1 liter TY
plus ampicillin and rhamnose. Gentamycin was also added for GB1b-RhaR. The cells were
grown to OD600 of 0.5, transferred to a 15 °C shaker, 0.1 mM IPTG was added, and then
incubated overnight. Cells were harvested by centrifugation and then resuspended in 30 mL
of cold binding buffer (20 mM Tris, 500 mM NaCl, 5 mM imidazole, pH 7.9) plus L-
rhamnose. Cells were lysed by three cycles of freeze thaw [with addition of lysozyme (0.4
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mg/mL), tris(2-carboxyethyl)phosphine (TCEP, 1 mM) and phenylmethylsulfonyl fluoride
(PMSF, 1 mM), at −80 °C] followed by sonication, and then centrifuged to remove cell
debris. The supernatant was applied using an AKTAexplorer FPLC (GE Healthcare) to a 5
mL HiTrap Chelating HP column (GE Healthcare) that had been charged with 50 mM
NiSO4, and equilibrated with 15 mL H20 and then 15 mL binding buffer. After loading, the
column was washed with 25 mL binding buffer, then 25 mL wash buffer (binding buffer, but
with 60 mM imidazole) plus L-rhamnose. A 10 mL gradient of binding buffer with 60 mM
to 250 mM imidazole was run and then 15 mL of elution buffer (binding buffer, but with
250 mM imidazole). The ArcticExpress cold-adapted chaperonins Cpn10 and Cpn60 (14
monomers per unit) co-purified with GB1b-RhaR, thus GB1b-RhaR represented only
approximately 20% of the total protein used in the assays.
In vitro DNA binding assays
Electrophoretic mobility shift assays were performed as described26, with the following
modifications. Reaction volumes were 12 µL total (with 5 µL loaded in each lane), in 1x
EMSA buffer [10 mM Tris-HCl (pH 7.4), 1 mM KEDTA, 50 mM KCl, 1 mM dithiothreitol,
5% (v/v) glycerol, 0.1 mg/mL bovine serum albumin (BSA) and 10 µg salmon sperm DNA].
Reactions also contained additives as follows: RhaS-GB1201b, L-rhamnose; GB1b-RhaR,
Nonidet P40 and L-rhamnose; CRP, cAMP; LacI, none. Purified proteins were buffer
exchanged into 1x EMSA buffer minus BSA and salmon sperm DNA, and without the
addition of additives. Electrophoresis was performed in 0.25× TBE (final concentrations:
22.25 mM Tris base, 22.25 mM boric acid, 500 µM disodium EDTA, pH 8.3). All EMSA
reactions, including those without inhibitor, had a final concentration of 10% DMSO
(OSSL_051168 solvent). DNA probes were generated by hybridizing the following
oligonucleotides (oligos): For RhaS-GB1201b, oligo 3058 (5’-
[IRD700]ACGTTCATCTTTCCCTGGTTGCCAATGGCCCATTTTCCTGTCAGTAACG
AGAAGGTCGCGAA-3’) and oligo 3288 (5’-
TTCGCGACCTTCTCGTTACTGACAGGAAAATGGGCCATTGGCAACCAGGGAAAG
ATGAACGT-3’); for GB1b-RhaR, oligo 3056 (5’-[IRD700]
CGCTGTATCTTGAAAAATCGACGTTTTTTACGTGGTTTTCCGTCGAAAATTTAAG
GTAAGAAC-3’) and oligo 3287 (5’-
GTTCTTACCTTAAATTTTCGACGGAAAACCACGTAAAAAACGTCGATTTTTCAA




LacI, oligo IR O1-For (5’-[IRD700]
TGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGG-3’) and oligo O1-Rev
(5’-CCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACA3’). IRD700- and
DY682-labeled oligos were from Eurofins MWG Operon. For each oligo pair, 100 µmol of
each oligo was combined and the reaction was diluted in STE buffer (50 mM NaCl, 10 mM
Tris-HCl, 1 mM EDTA, pH 8.0) to 20 µL, heated to 94°C for 2 min, and cooled to room
temperature. The double-stranded DNA probes were further diluted in STE, and 0.3–1 µL
added to EMSA reactions. To ensure that protein was limiting in the reactions, protein
concentrations were adjusted so that less than 100% of the total DNA was bound in the
absence of inhibitor (55–85% bound DNA among the replicates for all of the proteins
assayed). EMSA gels were imaged using an Odyssey infrared imager (LI-COR, Lincoln,
NE), and quantified using the Odyssey software, version 3.0.30. The quantity of DNA
bound with 10 µM inhibitor was approximately equal to the bound DNA in the absence of
inhibitor and was set to 100% for RhaS-GB1201b, GB1b-RhaR, and LacI. For CRP, the
quantity of DNA bound in the absence of inhibitor was set to 100%. Error bars represent the
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standard error of the mean. Inhibition values were calculated and graphs were drawn as for
in vivo dose-response experiments.
RESULTS
High-throughput screen to identify inhibitors of AraC family activators
Our goal was to use high throughput screening to identify novel inhibitors that could block
the function of AraC family activator proteins. Ultimately, such inhibitors have the potential
to be developed into antibacterial agents that block virulence factor expression in human
pathogens. Although it does not regulate virulence factor expression in any human
pathogens, we chose the RhaS protein as our initial target since the molecular mechanisms
used by RhaS to activate transcription are well characterized (for example18,26).
The first step of our in vivo high-throughput screen for RhaS inhibitors was to screen for
compounds that decreased expression of a RhaS-activated rhaB-lacZ reporter fusion in
whole cells (Fig. 1A, top). Screening in whole cells (rather than with purified protein) was
advantageous for two reasons. First, RhaS is very insoluble, and purified, active RhaS
protein was not available at the time of this screen. Second, whole-cell screens are expected
to identify only compounds that can enter, and remain active in the bacterial cell. The
disadvantage of our whole-cell assay was that many compounds were expected to affect
RhaS-activated LacZ reporter activity without directly affecting activation by RhaS. In order
to screen out the vast majority of such indirect effects, each compound that reduced the
RhaS-activated LacZ reporter activity in the primary screen was re-tested, both on the
primary screening strain and on a secondary screening strain. The secondary screening strain
was an isogenic control strain carrying a lacZ reporter fusion (hts-lacZ), with a synthetic
promoter that was repressed by LacI, and did not require RhaS for activation (Fig. 1A,
bottom). Non-specific inhibitors that blocked β-galactosidase enzyme activity or cell
growth, for example, were expected to decrease lacZ expression from both rhaB-lacZ and
hts-lacZ. In contrast, the compounds of interest that specifically inhibited RhaS were
expected to decrease lacZ expression from rhaB-lacZ (primary screen), but not from hts-
lacZ (secondary screen).
We screened a library of ~100,000 small-molecule compounds for those that decreased
rhaB-lacZ expression in the primary screening strain using a high-throughput β-
galactosidase assay (modified from19). All but three of the 295 plates (384-well) assayed
had Z-factors of 0.5 or above, and the remaining three plates had Z-factors above 0.4. (The
Z’ scores in the 0.4 range could be traced to one or two positive or negative control wells on
each plate with somewhat aberrant signals). The average of the Z-factors for all of the plates
was 0.7, indicating that this was an excellent assay20. A major contribution to the
performance of the assay was that the positive and negative controls had coefficients of
variation of only 2–3% over the entire assay.
The inducer for RhaS activation of rhaBAD transcription, L-rhamnose, was added to the
assay wells at the same time as the compounds. In this way, rhaB-lacZ expression was
uninduced until exposure to the compounds, and it wasn’t necessary for pre-formed β-
galactosidase to decay before inhibition could be detected. We further studied compounds
that resulted in rhaB-lacZ expression levels that were at least three standard deviations
below the mean of all of the compounds in the study. This allowed us to focus further efforts
on a convenient number of compounds likely to show significant inhibition. These
compounds decreased rhaB-lacZ expression levels to between zero and seventy-five percent
of the fully induced, non-inhibited control expression levels (data not shown).
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The ~300 most inhibitory compounds from the primary screen (~0.3% hit rate) were re-
assayed with both the RhaS-activated rhaB-lacZ fusion and the LacI-repressed control hts-
lacZ fusion (data not shown). IPTG, the inducer of the LacI-repressed hts-lacZ fusion, was
added to the assay wells at the same time as the compounds. Similar to addition of the
inducer L-rhamnose to the primary screen, this resulted in LacZ expression that was
uninduced until exposure to compounds. We ranked each compound by the difference in
lacZ expression levels between the RhaS-activated and the LacI-repressed fusions.
Expression levels were normalized to the average of the uninduced controls (set to 0%) and
the average of the induced controls (set to 100%). The data were plotted as a scatter plot of
the RhaS-activated (x-axis) versus LacI-repressed (y-axis) expression levels. Compounds
that inhibited expression from the RhaS-activated fusion to a greater extent than the LacI-
repressed fusion (upper left quadrant of plot) were likely specific inhibitors of RhaS activity,
and were of further interest. We selected the 16 compounds that best fit these criteria for
further study as potential specific RhaS inhibitors. These compounds exhibited considerable
structural diversity.
Dose-dependent inhibition of RhaS
We tested the effects of various concentrations of the 16 potential RhaS inhibitors on
activation of the RhaS-activated fusion compared with the LacI-repressed fusion to identify
those with dose-dependent inhibition (data not shown). The set of hits displayed
considerable structural diversity, including various heterocyclic ring systems having a range
of drug-like properties. One of the compounds showed particularly robust, dose-dependent
inhibition of the RhaS-activated fusion, and substantially less inhibition of the LacI-
repressed fusion. In addition, its structure was viewed as amenable for potential medicinal
chemistry optimization. We further describe studies of OSSL_051168, which is nearly
identical in structure to the compound identified in the screen, was readily available
commercially, and inhibited to the same extent as the screen compound (data not shown)
(Fig. 1B & C). We found that OSSL_051168 inhibited expression of the RhaS-activated
rhaB-lacZ fusion to a much greater extent than the LacI-repressed hts-lacZ fusion (Fig. 2,
circle and square markers). OSSL_051168 was able to fully inhibit expression of the RhaS-
activated fusion, and had an IC50 value of approximately 30 µM. Although there was a small
amount of non-specific inhibition, the majority of the OSSL_051168 inhibition appears to be
specific for RhaS. OSSL_051168 is not structurally related to any of the inhibitors of AraC
family activators that have been previously identified12–17.
OSSL_051168 inhibited the RhaS DNA-binding domain to the same extent as full-length
RhaS
The first step we took toward identifying the mechanism of RhaS inhibition by
OSSL_051168 was to determine whether the RhaS N-terminal domain was required for the
inhibitory effect. Proteins are defined as AraC family members if they contain a conserved
DNA binding domain that includes two helix-turn-helix motifs, as defined by Prosite entry
PS01124 (prosite.expasy.org/PS01124).2 The RhaS C-terminal DNA-binding domain alone
[residues 163 to 278, RhaS(163–278), previously published as RhaS-CTD] is capable of
activating transcription of the rhaB-lacZ fusion used in these studies, albeit to approximately
a three-fold lower level than full-length RhaS.27 We therefore compared the effect of
OSSL_051168 on activation of the RhaS-activated rhaB-lacZ fusion by full-length RhaS and
RhaS(163–278) (Fig. 2). We found that OSSL_051168 inhibited RhaS(163–278) to at least
the same extent as full-length RhaS. OSSL_051168 was again able to fully inhibit
expression, this time with an IC50 value of approximately 10 µM. This result indicates that
the RhaS N-terminal domain, which is required for dimerization and L-rhamnose binding, is
not required for OSSL_051168 inhibition of RhaS. We therefore conclude that
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OSSL_051168 specifically inhibits a function of the RhaS DNA-binding domain: likely
DNA binding or contacts with the RNA polymerase σ subunit.
OSSL_051168 does not inhibit cell growth
All of our assays to this point were performed in whole cells, thus it was important to test
whether OSSL_051168 had any significant effects on the growth of the bacterial cells. We
assayed the growth of the strains carrying the RhaS-activated and the LacI-repressed
fusions, grown in the same minimal medium used for the in vivo dose response assays. We
found that there was no impact of the inhibitor on the growth of the cells for either strain
(Fig. S1). There was a very slight divergence of the plus and minus inhibitor curves at the
end of the growth period, however this was not due to inhibitor toxicity, since the cells
grown without inhibitor had the slower growth. This result supports the hypothesis that the
inhibition we observed in the in vivo assays was likely due to specific inhibition of RhaS
activation.
OSSL_051168 inhibits in vitro DNA binding by RhaS and RhaR
In order to perform in vitro DNA binding assays with RhaS, we needed purified protein that
was soluble and active. With the exception of low levels of activity from denatured and
subsequently refolded protein28, we have not previously been able to observe in vitro DNA
binding by full-length RhaS, apparently due to its extremely low solubility. Two
modifications were required to obtain soluble and active RhaS for these studies. First, we
used a RhaS variant, RhaS L201R18, which binds DNA more strongly than wild-type RhaS.
The second modification was to fuse a GB1basic solubility-enhancement tag29 to the C-
terminus of full-length RhaS L201R, yielding RhaS L201R-GB1basic (referred to as RhaS-
GB1201b for brevity). The “basic” variant of GB1 was necessary to prevent tight binding
between RhaS and GB1 that blocked DNA binding (Skredenske, Deng and Egan,
unpublished). RhaS-GB1201b is soluble and binds DNA in vitro, with increased DNA
binding in the presence of L-rhamnose (Deng and Egan, unpublished), as expected for
functional RhaS based on previous studies28.
We used the electrophoretic mobility shift assay [EMSA] to investigate whether
OSSL_051168 inhibited in vitro DNA binding by RhaS-GB1201b. We incubated RhaS-
GB1201b with dsDNA containing the RhaS binding site sequence from the rhaBAD
promoter region (this includes binding sites for both monomers of the RhaS-GB1201b dimer)
in the absence or presence of various concentrations of OSSL_051168. We found that
OSSL_051168 was able to fully inhibit DNA binding by RhaS-GB1201b in a dose-dependent
manner (Fig. 3A). We calculated an IC50 of approximately 70 µM, which is in reasonable
agreement with the 30 µM IC50 calculated from the in vivo assays of RhaS inhibition,
especially considering the many experimental differences. From this result, we conclude that
the inhibition of RhaS activity observed in in vivo assays was likely due to OSSL_051168
blocking the ability of RhaS to bind to DNA.
We also tested the ability of OSSL_051168 to inhibit DNA binding by the RhaR protein. As
mentioned above, although RhaS and RhaR both activate transcription in response to the
effector L-rhamnose, they are only 30% identical to each other. The identity in their DNA
binding domains is approximately the same, at 34% amino acid identity. E. coli AraC family
activators have pairwise amino acid identities that range from single digits to 56%, thus
RhaS and RhaR share an intermediate level of identity
We purified RhaR as a fusion protein with GB1basic, GB1b-RhaR, which resulted in soluble
protein that was active for DNA binding – showing the expected increase in DNA binding in
the presence of L-rhamnose (Deng and Egan, unpublished). We found that OSSL_051168
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inhibited DNA binding by purified GB1b-RhaR protein to approximately the same extent as
RhaS-GB1201b protein (Fig. 3B). OSSL_051168 was able to fully inhibit GB1b-RhaR
binding to DNA, with an IC50 value of approximately 140 µM. The Hill coefficients for the
in vivo and in vitro assays of dimeric RhaS and RhaR were all approximately two [in
contrast to the Hill coefficient of approximately one for monomeric RhaS(163–278)] (data
not shown), suggesting possible positive cooperativity for inhibitor binding by full-length
dimeric RhaS and RhaR proteins.
OSSL_051168 does not inhibit DNA binding by non-AraC family proteins
Our results indicated that OSSL_051168 inhibits DNA binding by both the RhaS and RhaR
proteins. We used two unrelated proteins, the cyclic AMP receptor protein (CRP) and the
Lac repressor protein (LacI), to test whether OSSL_051168 was specific for inhibition of
RhaS and RhaR (and perhaps other AraC family proteins), or was broadly inhibitory toward
DNA binding proteins. CRP and LacI each share only 10–12% sequence identity with RhaS
and RhaR. Neither CRP nor LacI contains the two helix-turn-helix motifs (per monomer)
that is characteristic of AraC family proteins2. Broad inhibition of DNA binding by
OSSL_051168 would be expected to have a major impact on cell growth; therefore, the
finding that OSSL_051168 had minimal impact on growth of the strains used for our in vivo
studies (Fig. S1) was the first evidence that broad inhibition was unlikely.
We first tested the effect of OSSL_051168 on DNA binding by CRP. EMSA reactions were
performed with varying concentrations of purified CRP protein. The OSSL_051168
concentration (1.3 mM) was two-times higher than the concentration required in in vitro
assays to nearly eliminate RhaS binding to DNA. We found that even at this very high
concentration of OSSL_051168, approximately 94% of the CRP DNA binding was retained
(Fig. 4A). Thus, OSSL_051168 resulted in only a very slight inhibitory effect on DNA
binding by CRP.
As a second test of whether OSSL_051168 inhibition is specific for AraC family activators,
we tested the lac repressor protein, LacI (Fig. 4B). EMSA assays were again performed; in
this case various dilutions of OSSL_051168 (starting at 650 µM) were added to reactions
with LacI protein at a concentration just sufficient to shift nearly the entire DNA band. The
highest concentrations of OSSL_051168 had only a slight effect on LacI DNA binding, with
approximately 70% of DNA binding retained. Note that this in vitro test of LacI binding to
DNA was not redundant with the in vivo hts-lacZ reporter assay, since LacI was in its
induced state in the reporter assay, and therefore not bound to DNA.
Taken together, the CRP and LacI results indicate that OSSL_051168 doesn’t simply inhibit
the activity of all DNA binding proteins, and further that not all helix-turn-helix containing
proteins are inhibited. It has yet to be determined whether OSSL_051168 is specific for only
RhaS and RhaR. However, the above finding that OSSL_051168 inhibits RhaR, a protein
with only 30% identity with RhaS, suggests the possibility that OSSL_051168 might inhibit
DNA binding by additional AraC family proteins, perhaps including activators of virulence
factor expression in bacterial pathogens.
DISCUSSION
Screen Identified Inhibitors of AraC Family Activators
Members of the AraC family of transcriptional activators have excellent potential as targets
for novel antibacterial agents based on the fact that they are required for the expression of
virulence factors in many bacterial pathogens (for example,5–11). These include many
bacteria that pose serious human health threats due to their resistance to currently available
antibiotics. Thus, there is an urgent need for novel antibacterial agents. The goal of this
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study was to screen for and begin to characterize small molecule inhibitors of AraC family
transcriptional activators. Such inhibitors will be useful in the study of bacterial
pathogenesis, and have the potential to be developed into novel antibacterial agents.
Although several previous inhibitors of AraC family activators have been identified12–17,
the diversity of proteins in the family indicates the likelihood that the current inhibitors will
only be effective against a subset of family members.
We developed and validated a novel high throughput assay to screen for small molecule
inhibitors of the E. coli AraC family activator protein RhaS. The in vivo assay achieved
specificity for RhaS inhibitors through comparison of expression levels from two reporter
constructs; one that was transcriptionally activated by RhaS, and a second that was
transcriptionally repressed by the non-AraC family repressor LacI. The LacI-repressed
reporter enabled us to identify and eliminate non-specific inhibitors from consideration. Of
the compounds identified in our screen, we further investigated one compound,
OSSL_051168, which was an especially effective inhibitor of RhaS. OSSL_051168 is not
structurally related to any of the previously identified small molecule inhibitors of AraC
family activators, and thus is a novel inhibitor.
Specificity and Potency of OSSL_051168
Given that OSSL_051168 was identified through a whole-cell high throughput screen, and
has not undergone chemical optimization, its potency is very reasonable. The following
results indicate that the majority of the OSSL_051168 inhibition that we observed in whole
cell assays was specific for AraC family proteins. First, we found very little inhibition of
expression from the control fusion, hts-lacZ, indicating that there wasn’t significant
inhibition of β-galactosidase enzyme activity or of any processes that impacted transcription
or growth rate. The absence of an impact of OSSL_051168 on E. coli growth rate was more
directly confirmed by comparing cell growth rates in the absence and presence of
OSSL_051168. Finally, we determined that OSSL_051168 had only very little effect on
DNA binding by two proteins unrelated to the AraC family and unrelated to each other, CRP
and LacI. This result suggests that OSSL_051168 does not inhibit by a non-specific
mechanism such as binding to DNA to block protein binding. Since both CRP and LacI use
helix-turn-helix motifs to contact DNA, this finding also suggests that OSSL_051168
doesn’t generally block DNA binding by helix-turn-helix containing proteins. Therefore, it
appears that inhibition by OSSL_051168 involves binding to some feature that is unique to
RhaS, RhaR, and possibly additional AraC family activator proteins.
Mechanism of Action: OSSL_051168 Inhibits the Conserved AraC Family DNA Binding
Domain
In addition to their conserved DNA binding domains, the majority of AraC family proteins
contain a second, non-conserved, domain that regulates the activity of the DNA binding
domain, and in some cases imparts dimerization.2
The mechanism of action has been published for several previously identified AraC family
small molecule inhibitors. The first was Virstatin, which inhibits dimerization by binding to
the ToxT effector-binding pocket in the non-conserved domain and mimicking negative
regulators of ToxT activity, such as palmitoleic acid.30 The finding that Virstatin targets the
non-conserved AraC family protein domain suggests that it is likely to inhibit a relatively
narrow set of AraC family activators. (There are advantages and disadvantages to both
narrow and broad-spectrum antibacterial agents.) In contrast, the hydroxybenzimidazole
class of inhibitors targets a number of different AraC family proteins.12–14,17 Several
compounds in this class of inhibitors have been shown to block DNA binding.12–14,17
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Overall, the data from these publications supports a model in which the
hydroxybenzimidazole class of inhibitors targets the AraC family DNA binding domain.
Given the uncertainties inherent in the development of compounds into drugs, and the
enormous diversity of AraC family proteins, we screened for additional inhibitors of AraC
family activators, specifically the E. coli RhaS protein. We identified OSSL_051168, which
is a novel inhibitor of AraC family activators that is not structurally related to the previously
identified inhibitors. Our findings indicate that OSSL_051168 inhibits the activity of the
more conserved of the two RhaS domains, the DNA binding domain. Thus, OSSL_051168
might inhibit the activity of additional AraC family proteins; and indeed, we found that
OSSL_051168 also inhibited DNA binding by RhaR. Taken together, our results lead to the
hypothesis that the OSSL_051168 mechanism of action involves binding to the DNA
binding domain of AraC family proteins and blocking their ability to bind to DNA (Fig. S2).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Reporter fusions used in high-throughput screen and structure of OSSL_051168 compared
with compound identified in the screen. (A) Top: Primary screen, RhaS-activated rhaB-lacZ
fusion, shown in uninduced, (−)rhamnose state (left) and induced (+)rhamnose state (right).
Bottom: Secondary screen, LacI-repressed hts-lacZ control fusion, shown in uninduced,
(−)IPTG state (left) and induced (+)IPTG state (right). Gray rectangles: RhaS and LacI
(lacO) binding sites. Gray arrows: lacZ gene expressed from rhaBAD or synthetic hts
promoter. Thick black/gray line: Promoter region DNA. Right angle black arrow:
transcription start sites. Rounded gray shapes: RNAP, RhaS or LacI proteins. Wavy lines:
active transcription in the presence of inducers L-rhamnose (Rha) and IPTG. (B) The hit
from the high throughput screen, 1-ethyl-4-nitromethyl-3-quinolin-2-yl-4H-quinoline. (C)
OSSL_051168, 1-butyl-4-nitromethyl-3-quinolin-2-yl-4H-quinoline.
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In vivo effects of OSSL_051168 on β-galactosidase expression from the reporter fusions
hts-lacZ (SME3359, circles) and rhaB-lacZ activated by full-length RhaS (SME3634,
squares) or RhaS(163–278) (RhaS-DBD, SME3635, triangles). Activity in the absence of
inhibitor was set to 100% for each reporter fusion. Results are the average of three
independent experiments with two replicates each.
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Effect of OSSL_051168 on DNA binding by RhaS-GB1201b and GB1b-RhaR. The DNA
bound (assayed by EMSA) at the lowest concentration of inhibitor (OSSL_051168) was set
to 100%, and binding in all other cases is represented relative to that value. Inhibitor
concentrations ranged from 10 to 650 µM, with serial two-fold dilutions. Results are the
average of three independent experiments. (A) RhaS-GB1201b. Final concentrations of DNA
and protein were 2.5 nM and 2.4 µM, respectively. (B) GB1b-RhaR. Final concentrations of
DNA and protein were 1.3 nM and 2.2 µM, respectively.
Skredenske et al. Page 17














Effect of OSSL_051168 on DNA binding by non-AraC family activators. DNA binding was
assayed by EMSA. (A) CRP; at 480, 96 and 19 nM. DNA bound at 480 nM CRP in the
absence of inhibitor was set to 100%, and all other values are represented relative to that
value. OSSL_051168 was added at 1.3 mM where indicated. Final concentration of DNA
was 0.84 nM. Results are the average of two independent experiments. (B) LacI; the DNA
bound at the lowest concentration of inhibitor (OSSL_051168) was set to 100%, and binding
in all other cases is represented relative to that value. Inhibitor concentrations ranged from
20 to 650 µM, with serial two-fold dilutions. Results are the average of three independent
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experiments. Final concentrations of DNA and protein were 90 nM and 5.6 µM,
respectively.
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